Should I buy or sell Biohaven stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BHVN shares. View BHVN analyst ratings or view top-rated stocks .

What is Biohaven's stock price target for 2024?

8 Wall Street analysts have issued twelve-month price objectives for Biohaven's shares. Their BHVN share price targets range from $28.00 to $63.00. On average, they expect the company's stock price to reach $52.00 in the next year. This suggests a possible upside of 23.3% from the stock's current price. View analysts price targets for BHVN or view top-rated stocks among Wall Street analysts .

How have BHVN shares performed in 2024?

Biohaven's stock was trading at $42.80 at the beginning of 2024. Since then, BHVN stock has decreased by 1.5% and is now trading at $42.16. View the best growth stocks for 2024 here .

When is Biohaven's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our BHVN earnings forecast .

How were Biohaven's earnings last quarter?

Biohaven Ltd. (NYSE:BHVN) issued its earnings results on Thursday, February, 29th. The company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.41) by $0.40.

What ETFs hold Biohaven's stock?

ETFs with the largest weight of Biohaven (NYSE:BHVN) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , SPDR S&P Biotech ETF (XBI) and Virtus LifeSci Biotech Clinical Trials ETF (BBC) . Direxion Daily S&P Biotech Bull 3x Shares (LABU) .

What other stocks do shareholders of Biohaven own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven investors own include AbbVie (ABBV) , NVIDIA (NVDA) , Micron Technology (MU) , Advanced Micro Devices (AMD) , Alibaba Group (BABA) , ACADIA Pharmaceuticals (ACAD) , QUALCOMM (QCOM) , Pfizer (PFE) , Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT) .

When did Biohaven IPO?

Biohaven (BHVN) raised $124 million in an IPO on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Who are Biohaven's major shareholders?

Biohaven's stock is owned by a variety of institutional and retail investors. Top institutional investors include Cypress Wealth Services LLC (0.01%). Insiders that own company stock include Declan Doogan , Elyse Stock , George C Clark , Gregory Bailey , Irina Antonijevic , James Engelhart , John W Childs , Julia P Gregory , Matthew Buten and Vlad Coric . View institutional ownership trends .

How do I buy shares of Biohaven?

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:BHVN

Biohaven (BHVN) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free BHVN Stock Alerts

$42.16

-1.87 (-4.25%)

(As of 04/18/2024 ET)

Compare

Today's Range: $41.00
▼
$43.31
50-Day Range: $43.64
▼
$59.74
52-Week Range: $12.35
▼
$62.21

Volume: 3.62 million shs
Average Volume: 1.22 million shs
Market Capitalization: $3.44 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $52.00

Get Biohaven alerts:

Biohaven MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 23.3% Upside
$52.00 Price Target
Short Interest: Bearish
10.50% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.64
Based on 15 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($5.85) to ($5.59) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.24 out of 5 stars

Medical Sector

516th out of 919 stocks

Pharmaceutical Preparations Industry

225th out of 406 stocks

3.5

Analyst's Opinion

Consensus Rating
Biohaven has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Biohaven has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
10.50% of the outstanding shares of Biohaven have been sold short.
Short Interest Ratio / Days to Cover
Biohaven has a short interest ratio ("days to cover") of 7.4.
Change versus previous month
Short interest in Biohaven has recently decreased by 0.70%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Biohaven does not currently pay a dividend.
Dividend Growth
Biohaven does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BHVN.

2.6

News and Social Media Coverage

News Sentiment
Biohaven has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 15 news articles for Biohaven this week, compared to 3 articles on an average week.
Search Interest
Only 14 people have searched for BHVN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 12 people have added Biohaven to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biohaven insiders have not sold or bought any company stock.
Percentage Held by Insiders
16.00% of the stock of Biohaven is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
88.78% of the stock of Biohaven is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Biohaven are expected to grow in the coming year, from ($5.85) to ($5.59) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Biohaven is -7.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biohaven is -7.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Biohaven has a P/B Ratio of 7.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Biohaven Stock (NYSE:BHVN)

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

BHVN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BHVN Stock News Headlines

April 18, 2024 | markets.businessinsider.com

Maintaining Buy Rating: Biohaven’s BHV-1300 Shows Promising Efficacy and Safety Profile

April 18, 2024 | markets.businessinsider.com

Biohaven Prices Offering Of $230 Mln Of Shares At $41/share; Stock Down In Pre-Market

April 18, 2024 | InvestorPlace (Ad)

The Next Nvidia?

The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.

April 18, 2024 | msn.com

Biohaven drops 4%, prices $230M share offering

April 18, 2024 | prnewswire.com

Biohaven Announces Pricing of $230 Million Public Offering of Common Shares

April 17, 2024 | finance.yahoo.com

Biohaven Announces Proposed Public Offering of Common Shares

April 17, 2024 | investing.com

Biohaven shares rise on positive early-stage drug data

April 17, 2024 | investing.com

Biohaven retains stock target despite trial delay

April 18, 2024 | InvestorPlace (Ad)

The Next Nvidia?

April 15, 2024 | seekingalpha.com

Biohaven stock slides 15% amid data presentations

April 15, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Biohaven Ltd. Amid Positive Clinical Outlook and Pipeline Potential

April 13, 2024 | prnewswire.com

Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates

April 11, 2024 | americanbankingnews.com

Biohaven's (BHVN) Overweight Rating Reiterated at Cantor Fitzgerald

April 10, 2024 | americanbankingnews.com

Biohaven's (BHVN) Outperform Rating Reaffirmed at Royal Bank of Canada

March 27, 2024 | msn.com

Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly

March 20, 2024 | finance.yahoo.com

Bullish Biohaven Insiders Loaded Up On US$23.8m Of Stock

March 13, 2024 | finance.yahoo.com

BHVN Apr 2024 80.000 call

March 13, 2024 | finance.yahoo.com

BHVN Oct 2024 90.000 call

March 13, 2024 | finance.yahoo.com

BHVN May 2024 70.000 call

March 12, 2024 | finance.yahoo.com

BHVN Apr 2024 45.000 put

March 12, 2024 | finance.yahoo.com

BHVN Oct 2024 30.000 call

March 7, 2024 | nasdaq.com

Interesting BHVN Put And Call Options For May 17th

March 5, 2024 | markets.businessinsider.com

Buy Rating Affirmed: Biohaven’s Innovative Pipeline and Financial Health Signal Promising Future

March 4, 2024 | markets.businessinsider.com

Buy Rating Affirmed: Biohaven Ltd. Poised for Key Milestones with Diverse Portfolio and Promising Lead Molecule BHV-7000

March 4, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Biohaven Ltd. on Strong Pipeline and Upcoming Drug Advancements

March 1, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Veeva Systems (VEEV), Xenon (XENE)

March 1, 2024 | realmoney.thestreet.com

Biohaven price target raised by $20 at TD Cowen, here's why

See More Headlines

Receive BHVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NYSE:BHVN
Previous Symbol: NASDAQ:BHVN
CUSIP: N/A
CIK: 1689813
Web: www.biohavenpharma.com
Phone: 203-404-0410
Fax: N/A
Employees: 239
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $52.00
High Stock Price Target: $63.00
Low Stock Price Target: $28.00
Potential Upside/Downside: +23.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.66)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-408,170,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -103.50%
Return on Assets: -80.78%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.98
Quick Ratio: 7.98

Sales & Book Value

Annual Sales: $462.51 million
Price / Sales: 7.44
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.34 per share
Price / Book: 7.90

Miscellaneous

Outstanding Shares: 81,600,000
Free Float: 68,541,000
Market Cap: $3.44 billion
Optionable: Optionable
Beta: 1.18

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Vladimir Coric M.D. (Age 53)
Chairman & CEO
Comp: $1.96M
Mr. Matthew Buten (Age 63)
Chief Financial Officer
Comp: $1.05M
Dr. Bruce D. Car DACVP (Age 62)
Ph.D., Chief Scientific Officer
Comp: $883.03k
Ms. Kimberly Gentile (Age 58)
Senior Vice President of Clinical Operations
Comp: $858.65k
Ms. Deb Young
Director of Regulatory Affairs & Operations
Mr. George C. Clark (Age 40)
VP & Chief Accounting Officer
Ms. Jennifer Porcelli
Vice President of Investor Relations
Mr. Warren Volles J.D.
General Counsel & Chief Legal Officer
Mr. Clifford Bechtold M.S.
President, GM of Biohaven Ireland & Chief Compliance Officer
Mr. John Tilton (Age 56)
Chief Commercial Officer of Rare Diseases

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BHVN Stock Analysis - Frequently Asked Questions

Should I buy or sell Biohaven stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BHVN shares.
View BHVN analyst ratings or view top-rated stocks.
What is Biohaven's stock price target for 2024?: 8 Wall Street analysts have issued twelve-month price objectives for Biohaven's shares. Their BHVN share price targets range from $28.00 to $63.00. On average, they expect the company's stock price to reach $52.00 in the next year. This suggests a possible upside of 23.3% from the stock's current price.
View analysts price targets for BHVN or view top-rated stocks among Wall Street analysts.
How have BHVN shares performed in 2024?: Biohaven's stock was trading at $42.80 at the beginning of 2024. Since then, BHVN stock has decreased by 1.5% and is now trading at $42.16.
View the best growth stocks for 2024 here.
When is Biohaven's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our BHVN earnings forecast.
How were Biohaven's earnings last quarter?: Biohaven Ltd. (NYSE:BHVN) issued its earnings results on Thursday, February, 29th. The company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.41) by $0.40.
What ETFs hold Biohaven's stock?: ETFs with the largest weight of Biohaven (NYSE:BHVN) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Direxion Daily S&P Biotech Bull 3x Shares (LABU).

What other stocks do shareholders of Biohaven own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).
When did Biohaven IPO?: Biohaven (BHVN) raised $124 million in an IPO on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.
Who are Biohaven's major shareholders?: Biohaven's stock is owned by a variety of institutional and retail investors. Top institutional investors include Cypress Wealth Services LLC (0.01%). Insiders that own company stock include Declan Doogan, Elyse Stock, George C Clark, Gregory Bailey, Irina Antonijevic, James Engelhart, John W Childs, Julia P Gregory, Matthew Buten and Vlad Coric.
View institutional ownership trends.
How do I buy shares of Biohaven?: Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:BHVN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Biohaven (BHVN) Stock Price, News & Analysis

Biohaven MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Biohaven Stock (NYSE:BHVN)

BHVN Stock Price History

BHVN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

BHVN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™